Solara Active Pharma Sciences Limited

NSEI:SOLARA Stock Report

Market Cap: ₹19.7b

Solara Active Pharma Sciences Past Earnings Performance

Past criteria checks 0/6

Solara Active Pharma Sciences's earnings have been declining at an average annual rate of -52.9%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been declining at an average rate of 0.02% per year.

Key information

-52.9%

Earnings growth rate

-65.3%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate-0.02%
Return on equity-21.0%
Net Margin-21.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Apr 19
Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Feb 23
Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Jan 04
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

May 12
Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Nov 08
Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Sep 30
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Aug 03
Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Jun 19
Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Dec 21
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

With EPS Growth And More, Solara Active Pharma Sciences (NSE:SOLARA) Is Interesting

Oct 28
With EPS Growth And More, Solara Active Pharma Sciences (NSE:SOLARA) Is Interesting

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

May 31
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Need To Know: Analysts Are Much More Bullish On Solara Active Pharma Sciences Limited (NSE:SOLARA) Revenues

May 11
Need To Know: Analysts Are Much More Bullish On Solara Active Pharma Sciences Limited (NSE:SOLARA) Revenues

Revenue & Expenses Breakdown
Beta

How Solara Active Pharma Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:SOLARA Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2314,069-3,0832,5030
30 Sep 2315,529-3252,4610
30 Jun 2314,661-2532,3590
31 Mar 2314,438-2222,3080
31 Dec 2214,240-2412,1500
30 Sep 2211,296-1,6442,2210
30 Jun 2211,928-1,2472,3190
31 Mar 2212,683-5812,3920
31 Dec 2113,517-342,5290
30 Sep 2116,7812,0232,4720
30 Jun 2116,7402,2932,3930
31 Mar 2116,1692,2142,3270
31 Dec 2014,6941,8262,2970
30 Sep 2013,8641,5812,2120
30 Jun 2013,4001,3042,1390
31 Mar 2013,2181,1462,0800
31 Dec 1914,1031,2312,0590
30 Sep 1914,2281,0392,0320
30 Jun 1914,1408451,9860
31 Mar 1913,8676141,9270
31 Mar 185,210607100

Quality Earnings: SOLARA is currently unprofitable.

Growing Profit Margin: SOLARA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SOLARA is unprofitable, and losses have increased over the past 5 years at a rate of 52.9% per year.

Accelerating Growth: Unable to compare SOLARA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SOLARA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.8%).


Return on Equity

High ROE: SOLARA has a negative Return on Equity (-20.99%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.